168 related articles for article (PubMed ID: 28698656)
21. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
22. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
23. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
24. Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.
Xu X; Han L; Duan L; Zhao Y; Yang H; Zhou B; Ma R; Yuan R; Zhou H; Liu Z
Br J Clin Pharmacol; 2013 Feb; 75(2):516-23. PubMed ID: 22804784
[TBL] [Abstract][Full Text] [Related]
25. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
27. RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.
Chu TQ; Li R; Shao MH; Ye JY; Han BH
Acta Pharmacol Sin; 2016 Nov; 37(11):1490-1498. PubMed ID: 27665847
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients.
Cheng H; Sun N; Sun X; Chen B; Li F; Feng J; Cheng L; Cao Y
Acta Biochim Biophys Sin (Shanghai); 2010 May; 42(5):311-7. PubMed ID: 20458443
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.
Hu L; Chen SH; Lv QL; Sun B; Qu Q; Qin CZ; Fan L; Guo Y; Cheng L; Zhou HH
Int J Environ Res Public Health; 2016 May; 13(6):. PubMed ID: 27249003
[TBL] [Abstract][Full Text] [Related]
30. Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.
Jia M; Zhu M; Wang M; Sun M; Qian J; Ding F; Chang J; Wei Q
Oncotarget; 2016 May; 7(18):25291-303. PubMed ID: 26993769
[TBL] [Abstract][Full Text] [Related]
31. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Han B; Gao G; Wu W; Gao Z; Zhao X; Li L; Qiao R; Chen H; Wei Q; Wu J; Lu D
Lung Cancer; 2011 May; 72(2):238-43. PubMed ID: 20943283
[TBL] [Abstract][Full Text] [Related]
32. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Kim SH; Kim MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY; Ling H; Lee GW
Am J Clin Oncol; 2015 Jun; 38(3):294-9. PubMed ID: 23689644
[TBL] [Abstract][Full Text] [Related]
33. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.
Yin JY; Meng XG; Qian CY; Li XP; Chen J; Zheng Y; Liu R; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2015 Mar; 36(3):375-84. PubMed ID: 25732572
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
Zhao X; Wang X; Wu W; Gao Z; Wu J; Garfield DH; Wang H; Wang J; Qian J; Li H; Jin L; Li Q; Han B; Lu D; Bai C
Cancer; 2012 Jul; 118(14):3587-98. PubMed ID: 22072145
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
37. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
39. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
[TBL] [Abstract][Full Text] [Related]
40. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity.
Chen J; Wu L; Wang Y; Yin J; Li X; Wang Z; Li H; Zou T; Qian C; Li C; Zhang W; Zhou H; Liu Z
Tumour Biol; 2016 Feb; 37(2):2275-84. PubMed ID: 26358256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
